(Q37259608)

19 August 2017

1 reference

title

Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine (English)

1 reference

19 August 2017

Thomas M Luby

1

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

995-1003

1 reference

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Immunotherapeutic strategies for high-risk bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

MUC1 as a target antigen for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 1B1: a novel anticancer therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Tobacco smoke induces CYP1B1 in the aerodigestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Immunocytochemical visualization of DNA adducts in mouse tissues and human white blood cells following treatment with benzo[a]pyrene or its diol epoxide. A quantitative approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Environmental and chemical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Inhibition of human cytochrome p450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Purification and immunological characterization of a novel cytochrome P450 from C3H/10T1/2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

The aryl hydrocarbon receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Aryl hydrocarbon receptor-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Tumor necrosis factor-alpha potentiates genotoxic effects of benzo[a]pyrene in rat liver epithelial cells through upregulation of cytochrome P450 1B1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Tumor necrosis factor-alpha modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver "stem-like" cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 1B1, a novel chemopreventive target for benzo[a]pyrene-initiated human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 1B1-Mediated Estrogen Metabolism Results in Estrogen-Deoxyribonucleoside Adduct Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Central tolerance: learning self-control in the thymus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Identification of T-cell epitopes for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Mobilizing the low-avidity T cell repertoire to kill tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

CD4 regulatory T cells in human cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Gene inoculation generates immune responses against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Human clinical trials of plasmid DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Use of viral vectors for the development of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Immunity to melanoma antigens: from self-tolerance to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Electroporation-based DNA immunisation: translation to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

DNA vaccines: precision tools for activating effective immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Microparticle-based technologies for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Comparative methodologies of regulatory T cell depletion in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.995

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.995

1 reference

19 August 2017

1 reference